Search Results

There are 50316 results for: content related to: Targeting triglycerides in secondary prevention: should we bother?

  1. You have free access to this content
    Lipid-lowering efficacy of atorvastatin

    Intervention Review

    The Cochrane Library

    Stephen P Adams, Michael Tsang and James M Wright

    Published Online : 12 MAR 2015, DOI: 10.1002/14651858.CD008226.pub3

  2. You have free access to this content
    Lipid-lowering efficacy of rosuvastatin

    Intervention Review

    The Cochrane Library

    Stephen P Adams, Sarpreet S Sekhon and James M Wright

    Published Online : 21 NOV 2014, DOI: 10.1002/14651858.CD010254.pub2

  3. Treatment of Dyslipidemia and Cardiovascular Outcomes: The Journey So Far—Is This the End for Statins?

    Clinical Pharmacology & Therapeutics

    Volume 96, Issue 2, August 2014, Pages: 192–205, S Zoungas, A J Curtis, J J McNeil and A M Tonkin

    Version of Record online : 11 APR 2014, DOI: 10.1038/clpt.2014.86

  4. Low-Density Lipoprotein Apheresis: Principles and Indications

    Seminars in Dialysis

    Volume 25, Issue 2, March/April 2012, Pages: 145–151, Jeffrey L. Winters

    Version of Record online : 25 JAN 2012, DOI: 10.1111/j.1525-139X.2011.01025.x

  5. Friedewald equation underestimates low-density lipoprotein cholesterol at low concentrations in young people with and without Type 1 diabetes

    Diabetic Medicine

    Volume 27, Issue 1, January 2010, Pages: 37–45, L. Sibal, R. D. G. Neely, A. Jones and P. D. Home

    Version of Record online : 13 NOV 2009, DOI: 10.1111/j.1464-5491.2009.02888.x

  6. You have full text access to this OnlineOpen article
    PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia

    The Journal of Clinical Pharmacology

    Matthew K. Ito and Raul D. Santos

    Version of Record online : 21 JUN 2016, DOI: 10.1002/jcph.766

  7. You have free access to this content
    Low-Density Lipoprotein Reduction and Magnitude of Cardiovascular Risk Reduction

    Preventive Cardiology

    Volume 12, Issue 2, Spring 2009, Pages: 80–87, Catherine R. Rahilly-Tierney, Elizabeth V. Lawler, Richard E. Scranton and J. Michael Gaziano

    Version of Record online : 29 JAN 2009, DOI: 10.1111/j.1751-7141.2008.00018.x

  8. Chinese herbal medicines for hypercholesterolemia

    Intervention Review

    The Cochrane Library

    Zhao Lan Liu, Jian Ping Liu, Anthony Lin Zhang, Qiong Wu, Yao Ruan, George Lewith and Denise Visconte

    Published Online : 5 JUL 2011, DOI: 10.1002/14651858.CD008305.pub2

  9. You have free access to this content
    Population pharmacodynamic analysis of LDL-cholesterol lowering effects by statins and co-medications based on electronic medical records

    British Journal of Clinical Pharmacology

    Volume 78, Issue 4, October 2014, Pages: 824–835, Makoto Kakara, Hiroko Nomura, Masato Fukae, Keisuke Gotanda, Takeshi Hirota, Sunao Matsubayashi, Hideki Shimomura, Masaaki Hirakawa and Ichiro Ieiri

    Version of Record online : 19 SEP 2014, DOI: 10.1111/bcp.12405

  10. You have free access to this content
    Apolipoprotein B, non-HDL cholesterol and LDL cholesterol for identifying individuals at increased cardiovascular risk

    Journal of Internal Medicine

    Volume 268, Issue 6, December 2010, Pages: 567–577, S. Holewijn, M. Den Heijer, D. W. Swinkels, A. F. H Stalenhoef and J. De Graaf

    Version of Record online : 22 NOV 2010, DOI: 10.1111/j.1365-2796.2010.02277.x

  11. You have free access to this content
    Emerging innovative therapeutic approaches targeting PCSK9 to lower lipids

    Clinical Pharmacology & Therapeutics

    Volume 99, Issue 1, January 2016, Pages: 59–71, GPS Shantha and JG Robinson

    Version of Record online : 20 NOV 2015, DOI: 10.1002/cpt.281

  12. PCSK9 Inhibitors: Are We on the Verge of a Breakthrough?

    Clinical Pharmacology & Therapeutics

    Volume 98, Issue 6, December 2015, Pages: 590–601, E Yang

    Version of Record online : 8 OCT 2015, DOI: 10.1002/cpt.263

  13. Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study

    International Journal of Clinical Practice

    Volume 62, Issue 4, April 2008, Pages: 539–554, J. P. D. Reckless, P. Henry, T. Pomykaj, S. T. Lim, R. Massaad, K. Vandormael, A. O. Johnson-Levonas, K. Lis, P. Brudi and C. Allen

    Version of Record online : 11 FEB 2008, DOI: 10.1111/j.1742-1241.2008.01697.x

  14. You have full text access to this OnlineOpen article
    Efficacy and Safety of Alirocumab as Add-on Therapy in High–Cardiovascular-Risk Patients With Hypercholesterolemia Not Adequately Controlled With Atorvastatin (20 or 40 mg) or Rosuvastatin (10 or 20 mg): Design and Rationale of the ODYSSEY OPTIONS Studies

    Clinical Cardiology

    Volume 37, Issue 10, October 2014, Pages: 597–604, Jennifer G. Robinson, Helen M. Colhoun, Harold E. Bays, Peter H. Jones, Yunling Du, Corinne Hanotin and Stephen Donahue

    Version of Record online : 30 SEP 2014, DOI: 10.1002/clc.22327

  15. Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response

    Journal of Viral Hepatitis

    Volume 19, Issue 5, May 2012, Pages: 332–340, P. J. Clark, A. J. Thompson, M. Zhu, D. M. Vock, Q. Zhu, D. Ge, K. Patel, S. A. Harrison, T. J. Urban, S. Naggie, J. Fellay, H. L. Tillmann, K. Shianna, S. Noviello, L. D. Pedicone, R. Esteban, P. Kwo, M. S. Sulkowski, N. Afdhal, J. K. Albrecht, D. B. Goldstein, J. G. McHutchison, A. J. Muir and for the IDEAL investigators

    Version of Record online : 22 FEB 2012, DOI: 10.1111/j.1365-2893.2011.01553.x

  16. You have full text access to this Open Access content
    High Density GWAS for LDL Cholesterol in African Americans Using Electronic Medical Records Reveals a Strong Protective Variant in APOE

    Clinical and Translational Science

    Volume 5, Issue 5, October 2012, Pages: 394–399, Laura J. Rasmussen-Torvik, Jennifer A. Pacheco, Russell A. Wilke, William K. Thompson, Marylyn D. Ritchie, Abel N. Kho, Arun Muthalagu, M. Geoff Hayes, Loren L. Armstrong, Douglas A. Scheftner, John T. Wilkins, Rebecca L. Zuvich, David Crosslin, Dan M. Roden, Joshua C. Denny, Gail P. Jarvik, Christopher S. Carlson, Iftikhar J. Kullo, Suzette J. Bielinski, Catherine A. McCarty, Rongling Li, Teri A. Manolio, Dana C. Crawford and Rex L. Chisholm

    Version of Record online : 23 AUG 2012, DOI: 10.1111/j.1752-8062.2012.00446.x

  17. Optimal lipid targets for the new era of cardiovascular prevention

    Annals of the New York Academy of Sciences

    Volume 1254, Issue 1, April 2012, Pages: 106–114, Vimal Ramjee, Danny J. Eapen and Laurence S. Sperling

    Version of Record online : 30 APR 2012, DOI: 10.1111/j.1749-6632.2012.06478.x

  18. You have free access to this content
    Management of lipid disorders in patients living with HIV

    The Journal of Clinical Pharmacology

    Volume 55, Issue 9, September 2015, Pages: 957–974, Merle Myerson, Carlos Malvestutto and Judith A. Aberg

    Version of Record online : 23 JUN 2015, DOI: 10.1002/jcph.473

  19. You have free access to this content
    Effects of policosanol treatment on the susceptibility of low density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification in vitro

    British Journal of Clinical Pharmacology

    Volume 50, Issue 3, September 2000, Pages: 255–262, Roberto Menéndez, Rosa Más, Ana MA. Amor, Rosa MA. González, Julio C. Fernández, Idania Rodeiro, Mirta Zayas and Sonia Jiménez

    Version of Record online : 24 DEC 2001, DOI: 10.1046/j.1365-2125.2000.00250.x

  20. You have free access to this content
    Cardiovascular Disease, Mortality Risk, and Healthcare Costs by Lipoprotein(a) Levels According to Low-density Lipoprotein Cholesterol Levels in Older High-risk Adults

    Clinical Cardiology

    Volume 39, Issue 7, July 2016, Pages: 413–420, Yanglu Zhao, Joseph A. Delaney, Ruben G.W. Quek, Julius M. Gardin, Calvin H. Hirsch, Shravanthi R. Gandra and Nathan D. Wong

    Version of Record online : 13 MAY 2016, DOI: 10.1002/clc.22546